Why Acorda Therapeutics Stock Is Down Nearly 90%
Portfolio Pulse from Henry Khederian
Acorda Therapeutics Inc (NASDAQ:ACOR) shares plummeted nearly 90% after announcing Chapter 11 bankruptcy proceedings and an asset purchase agreement with Merz Therapeutics for $185 million. The agreement includes the sale of key drugs like INBRIJA, AMPYRA, and FAMPYRA. Despite the bankruptcy filing, Acorda plans to continue operations and aims to ensure uninterrupted medication supply to patients. The company had previously canceled its Q4 and year-end 2023 earnings call but will still file its Annual Report for 2023.
April 02, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Acorda Therapeutics Inc's stock plummeted nearly 90% following the announcement of Chapter 11 bankruptcy proceedings and an asset sale to Merz Therapeutics.
The significant drop in Acorda Therapeutics' stock price is directly related to the announcement of its Chapter 11 bankruptcy proceedings and the sale of major assets to Merz Therapeutics. Bankruptcy filings typically lead to a loss of investor confidence and can significantly impact stock prices negatively in the short term. The sale of key assets, while providing some liquidity, also indicates a potential stripping of valuable resources, further contributing to the negative outlook.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100